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ing requirements. Mobile phones provide a very effective method
of collecting data in an unsupervised, naturalistic setting.
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Following the FDA recommendations of having exhaustive, reli-
able and documented information on an instrument and its
translations when using these in an international study (draft
PRO guidance in 2006), the accessibility of this information for
instrument users has become increasingly important. The
quality of this information is however directly impacted by how
a developer chooses to release the latter into the scientiﬁc com-
munity and the way he decides to protect his instrument. It is
thus necessary to review current ways in which this is done, to
determine if FDA recommendations can actually be met or not
and explore ways in which to facilitate this. Methods included
to conduct a review of existing ways in which developers release
information into the scientiﬁc community; 2) to comment on
the pros and cons for each identiﬁed system with concrete
examples; and 3) to make recommendations for instrument
developers. Out of the 50 different cases identiﬁed and
reviewed, two trends emerge with all possible variations
between the following two extremes: on the one hand, the
uncontrolled, de-centralised, free access to non-updated infor-
mation without developer input and on the other controlled,
copyright-protected, centralized, fee-paying access to reliable
and updated information with input of the developer. Whilst
both extremes have advantages and disadvantages, results dem-
onstrate that the latter extreme seems to be more compliant
with FDA recommendations. Concrete examples will be dis-
cussed in the presentation. Findings indicate that the way in
which a developer organises (or not) the release of information
on his instrument and its translations is directly related to
whether a user can comply or not with FDA recommendations.
Promoting a controlled, centralized system with input from the
developers will facilitate access to reliable and updated infor-
mation on instruments and their translations.
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OBJECTIVE: Handheld computer systems are increasingly being
used to administer performance tasks and mood assessments in
an everyday life setting. Mobile phones (cell) phones can be used
in a similar way, and are highly portable and widely used. We
evaluated a mobile phone implementation of a VAS scale using
alcohol as a means of producing changes in subjective state.
METHODS: Sixty-ﬁve volunteers (30 male) aged 19–54 years
(mean 23) consumed a drink containing either vodka or water
and orange juice in 10 minutes. Mean breath alcohol concentra-
tion 60 minutes later was 45–170 mg/100 ml (mean 94). Subjec-
tive drunkenness was rated on the mobile phone and on paper in
randomised order before the drink and at 60 minutes after the
drink with other test procedures in between. RESULTS: Changes
in sober–drunk ratings (% of scale length) due to alcohol were
comparable between the two testing modes (Alcohol—Placebo:
29.3 for phone, 25.3 for paper) and the agreement was excellent
(Intra-Class Correlation = 0.96). The sensitivity to changes in
scores between alcohol and placebo was similar for the two
modes. CONCLUSION: We have shown that ratings made on a
2.1 cm VAS on a mobile phone screen are very similar to those on
a conventional 10 cm scale on paper. Taken together with work
on handheld devices, these data suggest that VAS scores are
unaffected by scale length over a rather wide range, and support
the use of mobile phone and handheld implementations of VAS
for assessing subjective states.
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OBJECTIVE: Due to the existence of many methods for esti-
mating MCID and a lack of consensus on choosing among the
potential estimates, an integrated approach for generating a
MCID change score on Patient Reported Outcomes (PRO)
measures is proposed. When incorporating PRO in clinical
trials, clinicians and researchers face the challenge of determin-
ing whether a mean difference on a measure is clinically impor-
tant. Currently available methods for interpreting the scores on
PRO measures are often classiﬁed as being either anchor-based
or distribution-based. These methods may yield a variety
of candidates as potential MCID estimates. However, there is
no agreed method of choosing among these candidates.
METHODS: A strategy is proposed that integrates these two
methods of MCID estimation and extends to selection among
the candidate values by incorporating their natural variability
and distinctions as well as the critical role of clinical judgment.
The strategy consists of three steps: 1) generating multiple esti-
mates of a MCID and corresponding conﬁdence intervals (CIs)
and range of variability; 2) integrating across the estimates
from Step 1 by applying adopted normative descriptive criteria
for MCID; 3) incorporating clinical judgment. An illustration
of the proposed strategy is provided. RESULTS: Across the
candidate MCID values, the maximum, minimum, mean of the
estimates, minimum and mean of the 80% CI lower bounds, as
well as the range of variability, were selected with consideration
given to clinical insight. The comprehensive paradigm resulted
in a MCID estimate that integrates normative, descriptive cri-
teria. CONCLUSION: The proposed paradigm serves as a uni-
fying approach that integrates available methods for estimating
a MCID for a PRO.
PMC40
PHARMACY STUDENTS’ PERCEPTIONS OF HEALTH-RELATED
QUALITY OF LIFE FOR MULTIPLE CHRONIC HEALTH STATES
MEASUREDVIA ALTERNATIVE METHODS FOR UTILITY
ASSESSMENT
Patel RA,Walberg MP
University of the Paciﬁc, Stockton, CA, USA
OBJECTIVES: To measure and analyze utility value assignment
by professional pharmacy students to each of four chronic health
states (Depression, Type 1 Diabetes, Rheumatoid Arthritis, and
Hypertension) through utilization of one of the following utility
assessment techniques: visual analog scale (VAS), feeling ther-
mometer (FT), standard gamble (SG), and time-trade off (TTO).
METHODS: Each Doctor of Pharmacy student (n = 195) was
provided with a detailed patient vignette for each health state
under evaluation. These cases contained information including
the patient’s drug therapy, overall health state and the impact of
the latter on activities of daily living. Much care was given to
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